GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AP Biosciences 6945.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

112.00

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About AP Biosciences

Its shares trade on Taipei Exchange under the ticker 6945.TWO. It has been listed since 14 July 2023. In the fiscal year to 31 December 2023, it reported revenue of TWD 32.3m and a net loss of TWD 339.3m. At that date it held total assets of TWD 890.8m and shareholders' equity of TWD 784.1m.

AP Biosciences Inc is a TW-based company operating in Biotechnology industry. The company is headquartered in Taipei City, Taipei. The company went IPO on 2023-07-14. AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The firm develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The firm's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
14 Jul 2023
Employees
26
Website
apbioinc.com ↗

Leadership

Pay as last reported

  • Weilun LuoDeputy General Manager-Business Development Department
  • Fucheng HuangHead of Accounting & Finance
  • Mr. Su-Ming LinIndependent Director
  • Congzhi QiuIndependent Director
  • Mr. Hwei-Jiung WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in the Biotechnology sector with a focus on protein and antibody drug development.
  • The company has a technology platform for developing monoclonal and bispecific antibody drugs.
  • The company has a small employee count of 26 full-time employees.

Weaknesses

  • The company has a small employee count of 26 full-time employees.
  • The company went public in 2023, indicating a relatively new market presence.
  • The company's IPO date is 2023-07-14, suggesting limited historical market data.

Opportunities

  • The company's technology platform supports the development of bispecific antibody drugs for various targets.
  • The company is engaged in early candidate drug development and preclinical trials.
  • The company has multiple drug development projects including IBI302 and AP505.

Threats

  • The company is a new IPO with limited market history and data.
  • The biotechnology industry is highly competitive and requires significant R&D investment.
  • The company's small size may limit its ability to compete with larger biotech firms.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.